本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

ADC Therapeutics SA

1.79
+0.200012.58%
盘后1.71-0.0800-4.47%19:00 EST
成交量:58.82万
成交额:97.51万
市值:1.73亿
市盈率:-0.77
高:1.79
开:1.58
低:1.50
收:1.59
数据加载中...

公司资料

公司名字:
ADC Therapeutics SA
交易所:
NYSE
成立时间:
2011
员工人数:
274
公司地址:
BiopOle,Route de la Corniche 3B,Epalinges,Vaud,Switzerland
邮编:
1066
传真:
- -
简介:
ADC Therapeutics SA于2011年6月6日根据瑞士法律注册成立。该公司是一家完全整合的商业阶段生物技术公司,通过下一代靶向抗体药物偶联物帮助改善癌症患者的生活。该公司的旗舰产品ZYNLONTA(loncastuximab tesirine或Lonca)于2021年4月23日获得FDA的加速批准,并在此后不久在美国上市,用于治疗经过两个或两个以上系统治疗的复发或难治性大B细胞淋巴瘤成人患者,包括未另行说明的弥漫性大B细胞淋巴瘤、由低级别淋巴瘤引起的DLBCL,以及高级别B细胞淋巴瘤。该公司的目标是将ZYNLONTA确立为三线+ DLBCL护理标准,同时探索ZYNLONTA在早期治疗和组合中的应用,以扩大市场机会。

董事

名称
职位
Christopher Martin
Chief Executive Officer and Director
Michael Forer
Executive Vice President, Chief Financial Officer and Vice Chairman of the Board, General Counsel
Ron Squarer
Chairman of the Board of Director
Jacques Theurillat
Director
Peter B. Corr
Director
Peter Hug
Director
Stephen Evans Freke
Director
Thomas M. Rinderknecht
Director
Thomas Pfisterer
Director
Tyrell J. Rivers
Director
Victor Sandor
Director

股东

名称
职位
Christopher Martin
Chief Executive Officer and Director
Jay Feingold
Senior Vice President, Chief Medical Officer & Head of Oncology
Jennifer Herron
Senior Vice President, Chief Commercial Officer
Michael Forer
Executive Vice President, Chief Financial Officer and Vice Chairman of the Board, General Counsel
Patrick van Berkel
Senior Vice President, Research and Development
Peter Greaney
Head of Corporate Development
Richard Onyett
Vice President, Business Development
Stephane Henchoz
Director of Finance
Susan Romanus
Chief Compliance Officer